Lutris Pharma
Tel Aviv, Israel· Est.
Topical B‑Raf inhibitor that reduces EGFR‑inhibitor and radiation‑induced skin side effects.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Topical B‑Raf inhibitor that reduces EGFR‑inhibitor and radiation‑induced skin side effects.
Oncology
Technology Platform
Topical small‑molecule B‑Raf inhibitor that paradoxically activates skin signaling to counteract EGFR‑inhibitor and radiation‑induced dermal toxicities.
Opportunities
Addressing a large unmet need for effective management of EGFR‑inhibitor and radiation skin toxicities, with accelerated FDA pathways and potential licensing to major oncology firms.
Risk Factors
Reliance on successful Phase 2/3 outcomes, regulatory acceptance of topical B‑Raf inhibition, and limited financial runway as a pre‑revenue private company.
Competitive Landscape
Few competitors target the molecular cause of therapy‑induced skin toxicities; Lutris differentiates through its paradoxical B‑Raf inhibitor mechanism and topical formulation.